Becton, Dickinson and Company (BDX)
(Delayed Data from NYSE)
$237.17 USD
-0.29 (-0.12%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $237.10 -0.07 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$237.17 USD
-0.29 (-0.12%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $237.10 -0.07 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth B Momentum B VGM
Zacks News
Merit Medical Acquires Brightwater Medical for $35 Million
by Zacks Equity Research
The Brightwater Medical-acquisition broadens Merit Medical's (MMSI) product offerings.
Why Is Becton Dickinson (BDX) Up 3.7% Since Last Earnings Report?
by Zacks Equity Research
Becton Dickinson (BDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Stock Market News For May 9, 2019
by Zacks Equity Research
Wall Street closed mostly lower on Wednesday as trade tensions between the United States and China lingers.
Becton, Dickinson (BDX) Q2 Earnings Beat, Revenues Fall Y/Y
by Zacks Equity Research
Becton, Dickinson (BDX) gains from BD Medical in fiscal Q2; international revenues down.
Becton Dickinson (BDX) Q2 Earnings Beat Estimates
by Zacks Equity Research
Becton Dickinson (BDX) delivered earnings and revenue surprises of 0.78% and -0.98%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Can BD Medical Drive Becton, Dickinson's (BDX) Q2 Earnings?
by Zacks Equity Research
Becton, Dickinson (BDX) expects BD Medical to drive fiscal Q2 results; foreign exchange headwinds persist.
Analysts Estimate Becton Dickinson (BDX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Becton Dickinson (BDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights: Celgene, Schlumberger, Becton, Dickinson, Twitter and PPG Industries
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Celgene, Schlumberger, Becton, Dickinson, Twitter and PPG Industries
Top Analyst Reports for Celgene, Schlumberger & Becton, Dickinson
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Celgene (CELG), Schlumberger (SLB) and Becton, Dickinson (BDX).
Top Stock Reports for IBM, Honeywell & American Express
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including IBM (IBM), Honeywell (HON) and American Express (AXP).
The Zacks Analyst Blog Highlights: Eli Lilly, Altria, Becton, Dickinson, T-Mobile and General Motors
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Eli Lilly, Altria, Becton, Dickinson, T-Mobile and General Motors
Top Stock Reports for Eli Lilly, Altria & Becton Dickinson
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly (LLY), Altria (MO) and Becton, Dickinson (BDX).
BD Introduces New Product to Reduce the Risk of Sepsis
by Zacks Equity Research
BD introduces new FDA cleared product to lower the risk of sepsis and combat platelet contamination.
Here's Why You Should Hold Becton, Dickinson Stock for Now
by Zacks Equity Research
Becton, Dickinson (BDX) announces the FDA premarket approval for Venovo venous stent device.
BD Remains Confident About LUTONIX DCB Despite FDA Letter
by Zacks Equity Research
Per the recent press release issued by BD (BDX), it seems that the company still has immense confidence on the LUTONIX DCB.
Stock Market News For Mar 15, 2019
by Zacks Equity Research
Wall Street closed mixed on Thursday as investors??? remained anxious about the delay in sealing a U.S. ??? China trade deal.
BD's Venovo Gets FDA Nod, Interventional Arm to Get a Boost
by Zacks Equity Research
Becton, Dickinson (BDX) receives a number of regulatory approvals of late.
Becton Dickinson (BDX) Up 2.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Becton Dickinson (BDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Hold Becton, Dickinson Stock for Now
by Zacks Equity Research
Becton, Dickinson's (BDX) MAX enteric viral panel receives FDA clearance.
BD Gains From Solid Global Base, Headwinds Anticipated
by Zacks Equity Research
Becton, Dickinson's (BDX) solid geographical expansion encourages; raw material pricing pressure raises concern.
The Zacks Analyst Blog Highlights: Procter & Gamble, Becton, Dickinson, Dominion, Chubb and Estee Lauder
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Procter & Gamble, Becton, Dickinson, Dominion, Chubb and Estee Lauder
Top Analyst Reports for Procter & Gamble, Becton, Dickinson & Dominion Energy
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Procter & Gamble (PG), Becton, Dickinson (BDX) and Dominion Energy (D).
Market Awaits A Flood of Q4 2018 Earnings Data
by Zacks Equity Research
Market Awaits A Flood of Q4 2018 Earnings Data.
Heavy Q4 Reporting Ahead of State of the Union Address
by Mark Vickery
Investors will be playing close attention to the president's comments on taxes, spending and congressional harmony (or lack thereof).
Becton, Dickinson (BDX) Q1 Earnings In Line With Estimates
by Zacks Equity Research
Strong segmental performance favors Becton, Dickinson's (BDX) fiscal Q1 results.